• Anas Alrohimi, Kaylynn Purdy, Mustafa Alqarni, Ghazi Alotaibi, Gregg Blevins, Ken Butcher, Jeremy Rempel, Cynthia Wu, Haowei Linda Sun, and Khurshid Khan.
• Department of Medicine, Division of Neurology, University of Alberta, Edmonton, Canada.
• Can J Neurol Sci. 2021 Jan 1; 48 (1): 38-46.

AbstractGuidelines are lacking for management of acute ischemic stroke and stroke prevention in patients with immune thrombocytopenia (ITP). Our aim is to highlight the dilemma inherent in managing patients with both significant bleeding and thrombotic risk factors. In this review, we present two patients with history of ITP who presented with acute ischemic stroke and received tissue plasminogen activator (tPA) and endovascular thrombectomy (EVT), a rare management strategy in this patient population. In addition, we identified 27 case reports of ischemic stroke in patients with ITP; none of them received tPA or EVT. Furthermore, there are 92 patients with significant thrombocytopenia with no available data regarding the cause of thrombocytopenia, who were acutely treated with tPA or EVT. Conclusive evidence cannot be determined based on these limited number of cases. Future multicenter prospective cohort studies in patients with ITP are needed to provide better evidence-based treatment plans. At present, treatment of acute ischemic stroke in patients with ITP requires close collaboration between hematology and vascular neurology experts to find a balance between the benefit and risk of hemorrhagic complications.

5 keywords...

hide…